Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NYSE:BHVN NASDAQ:MRUS NASDAQ:RNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$91.67+0.2%$83.50$4.77▼$98.64$7.12B0.391.07 million shs458,364 shsBHVNBiohaven$17.76+1.2%$15.27$12.79▼$54.98$1.86B1.032.32 million shs1.82 million shsMRUSMerus$94.60+0.2%$76.50$33.19▼$95.04$7.14B1.265.04 million shs1.52 million shsRNAAvidity Biosciences$49.05+0.1%$45.72$21.51▼$56.00$7.15B0.971.82 million shs933,141 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax-1.34%-4.33%+11.17%+814.90%+775.50%BHVNBiohaven+9.59%+14.72%+22.28%+30.81%-66.89%MRUSMerus-0.47%-0.43%+38.43%+49.29%+79.24%RNAAvidity Biosciences+2.34%+0.10%+19.36%+46.17%-2.85%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$91.67+0.2%$83.50$4.77▼$98.64$7.12B0.391.07 million shs458,364 shsBHVNBiohaven$17.76+1.2%$15.27$12.79▼$54.98$1.86B1.032.32 million shs1.82 million shsMRUSMerus$94.60+0.2%$76.50$33.19▼$95.04$7.14B1.265.04 million shs1.52 million shsRNAAvidity Biosciences$49.05+0.1%$45.72$21.51▼$56.00$7.15B0.971.82 million shs933,141 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax-1.34%-4.33%+11.17%+814.90%+775.50%BHVNBiohaven+9.59%+14.72%+22.28%+30.81%-66.89%MRUSMerus-0.47%-0.43%+38.43%+49.29%+79.24%RNAAvidity Biosciences+2.34%+0.10%+19.36%+46.17%-2.85%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 2.91Moderate Buy$114.2524.63% UpsideBHVNBiohaven 3.00Buy$48.85175.07% UpsideMRUSMerus 2.16Hold$93.12-1.57% DownsideRNAAvidity Biosciences 2.95Moderate Buy$67.7838.18% UpsideCurrent Analyst Ratings BreakdownLatest BHVN, RNA, MRUS, and ABVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/13/2025ABVXAbivaxBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$142.0010/13/2025ABVXAbivaxBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$142.0010/10/2025ABVXAbivaxGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$101.00 ➝ $150.0010/8/2025ABVXAbivaxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025BHVNBiohavenWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025MRUSMerusWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025RNAAvidity BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/6/2025ABVXAbivaxBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$112.00 ➝ $120.0010/6/2025MRUSMerusLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$95.00 ➝ $97.0010/5/2025MRUSMerusLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/30/2025MRUSMerusUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$72.00 ➝ $97.00(Data available from 10/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$0.69 per shareN/ABHVNBiohavenN/AN/AN/AN/A$4.19 per shareN/AMRUSMerus$36.13M198.02N/AN/A$9.46 per share10.00RNAAvidity Biosciences$10.90M656.55N/AN/A$11.94 per share4.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$190.71MN/A0.00N/AN/AN/AN/AN/AN/ABHVNBiohaven-$846.42M-$7.66N/AN/AN/AN/A-270.65%-143.70%11/11/2025 (Estimated)MRUSMerus-$215.33M-$5.50N/AN/AN/A-685.64%-50.28%-42.00%10/30/2025 (Estimated)RNAAvidity Biosciences-$322.30M-$3.56N/AN/AN/A-4,247.77%-33.45%-30.22%11/6/2025 (Estimated)Latest BHVN, RNA, MRUS, and ABVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025BHVNBiohaven-$1.90N/AN/AN/A$0.34 millionN/A11/6/2025Q3 2025RNAAvidity Biosciences-$1.09N/AN/AN/A$1.80 millionN/A10/30/2025Q3 2025MRUSMerus-$1.20N/AN/AN/A$8.73 millionN/A9/8/2025Q2 2025ABVXAbivax-$0.90-$0.86+$0.04-$0.86$1.35 millionN/A8/11/2025Q1 2025BHVNBiohaven-$1.94-$1.94N/A-$1.94$0.41 millionN/A8/5/2025Q1 2025MRUSMerus-$1.17-$2.23-$1.06-$2.23$9.77 million$8.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/ABHVNBiohavenN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ARNAAvidity BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivaxN/A0.770.77BHVNBiohaven1.913.823.82MRUSMerusN/A8.398.39RNAAvidity BiosciencesN/A9.269.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%BHVNBiohaven88.78%MRUSMerus96.14%RNAAvidity BiosciencesN/AInsider OwnershipCompanyInsider OwnershipABVXAbivaxN/ABHVNBiohaven14.60%MRUSMerus3.70%RNAAvidity Biosciences3.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6177.83 millionN/ANot OptionableBHVNBiohaven239105.79 million90.35 millionOptionableMRUSMerus3775.63 million72.84 millionOptionableRNAAvidity Biosciences190145.90 million140.32 millionOptionableBHVN, RNA, MRUS, and ABVX HeadlinesRecent News About These CompaniesPrivium Fund Management B.V. Has $1.31 Million Holdings in Avidity Biosciences, Inc. $RNAOctober 21 at 6:04 AM | marketbeat.comAvidity Biosciences, Inc. $RNA Stock Holdings Cut by TD Asset Management IncOctober 19 at 4:13 AM | marketbeat.comTeresa Mccarthy Sells 20,000 Shares of Avidity Biosciences (NASDAQ:RNA) StockOctober 18 at 4:38 PM | marketbeat.comWill FDA Feedback and Del-Zota BLA Timeline Shift Redefine Avidity Biosciences' (RNA) Late-Stage Pipeline?October 17, 2025 | finance.yahoo.comAvidity Biosciences to Participate in Upcoming Investor ConferenceOctober 16, 2025 | prnewswire.comAvidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026October 13, 2025 | prnewswire.comWhat Makes Avidity Biosciences (RNA) an Investment Choice?October 13, 2025 | insidermonkey.comAvidity Biosciences (NASDAQ:RNA) Receives "Sell (D-)" Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Insider Eric Mosbrooker Sells 6,562 SharesOctober 7, 2025 | marketbeat.comAvidity Biosciences (RNA): Assessing Valuation Following Recent Positive Share Price MomentumOctober 6, 2025 | finance.yahoo.comAvidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle SocietyOctober 6, 2025 | prnewswire.comAvidity Biosciences, Inc. (NASDAQ:RNA) Given Consensus Recommendation of "Moderate Buy" by AnalystsOctober 4, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Shares Down 7.6% - Here's What HappenedSeptember 29, 2025 | marketbeat.comAssenagon Asset Management S.A. Has $507,000 Position in Avidity Biosciences, Inc. $RNASeptember 28, 2025 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Avidity Biosciences (RNA), Crinetics Pharmaceuticals (CRNX)September 24, 2025 | theglobeandmail.comAvidity Biosciences (RNA) Announces Positive One-Year Data For its, Del-ZotaSeptember 24, 2025 | msn.comSteven George Hughes Sells 2,208 Shares of Avidity Biosciences (NASDAQ:RNA) StockSeptember 24, 2025 | insidertrades.comAvidity Biosciences (NASDAQ:RNA) Insider Sells $89,600.64 in StockSeptember 23, 2025 | marketbeat.comEvercore ISI Cuts Avidity Biosciences (NASDAQ:RNA) Price Target to $65.00September 22, 2025 | marketbeat.comRoth Capital Initiates Coverage of Avidity Biosciences (RNA) with Buy RecommendationSeptember 18, 2025 | msn.comAvidity raises $690m to advance RNA pipeline and Duchenne therapySeptember 16, 2025 | thepharmaletter.comTNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesGameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound?By Dan Schmidt | September 22, 2025Klarna IPO: BNPL Stock or Something Bigger?By Chris Markoch | September 28, 2025Nike’s Turnaround: If the Shoe Fits, Buy It!By Thomas Hughes | October 2, 2025These 3 Crypto Stocks Could Get a Bump as Dollar Trust WeakensBy Nathan Reiff | September 27, 20253 International Stocks with Rising Short InterestBy Chris Markoch | September 23, 2025BHVN, RNA, MRUS, and ABVX Company DescriptionsAbivax NASDAQ:ABVX$91.67 +0.18 (+0.20%) Closing price 04:00 PM EasternExtended Trading$91.63 -0.04 (-0.04%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Biohaven NYSE:BHVN$17.76 +0.22 (+1.24%) Closing price 03:59 PM EasternExtended Trading$17.85 +0.09 (+0.52%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Merus NASDAQ:MRUS$94.60 +0.16 (+0.17%) Closing price 04:00 PM EasternExtended Trading$94.07 -0.53 (-0.56%) As of 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Avidity Biosciences NASDAQ:RNA$49.05 +0.04 (+0.08%) Closing price 04:00 PM EasternExtended Trading$48.72 -0.32 (-0.66%) As of 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
